Linaclotide vs Plecanatide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Linaclotide (Linzess) is a 14-amino acid synthetic peptide that is a structural and functional analog of the endogenous guanylate cyclase-C (GCC) agonists guanylin and uroguanylin. FDA-approved in 2012, it treats irritable bowel syndrome with constipation (IBS-C) and chronic idio...
Calculate Linaclotide dose →Plecanatide (Trulance) is a synthetic 16-amino acid analog of uroguanylin, an endogenous guanylate cyclase-C agonist produced in duodenal cells. FDA-approved in 2017 for chronic idiopathic constipation and in 2018 for IBS-C, plecanatide is structurally similar to uroguanylin and ...
Calculate Plecanatide dose →| Parameter | Linaclotide | Plecanatide |
|---|---|---|
| Category | GI Peptide / Secretagogue | GI Peptide / Secretagogue |
| Research | FDA Approved | FDA Approved |
| Half-Life | <2 hours (luminal) | <2 hours (luminal) |
| Typical Dose | 72-290 mcg once daily | 3 mg once daily |
| Frequency | Once daily | Once daily |
| Route | Oral | Oral |
| FDA Status | Approved (IBS-C, CIC) 2012 | Approved (CIC, IBS-C) 2017 |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.